On July 11, 2023 Stanford University and Cofactor Genomics, the company bridging the precision medicine gap, reported that Stanford will join Cofactor’s PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) clinical trial evaluating use of the company’s OncoPrism predictive diagnostic assay across 11 cancers (Press release, Stanford University, JUL 11, 2023, View Source [SID1234633186]). Cofactor’s patented approach to building multidimensional immune biomarkers powers OncoPrism, which has been shown to predict tumor response to immunotherapy with almost twice the accuracy of PD-L1 tests.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stanford University joins more than 20 healthcare and hospital systems currently enrolling patients in the PREDAPT Trial with an approved protocol to study OncoPrism in patients with 11 types of cancer, including triple-negative breast, cervical, colorectal, esophageal, gastric, head and neck, kidney, liver, lung, and urothelial cancers. Immunotherapies produce durable and lasting results for a subpopulation of patients, but currently available diagnostics powered by single-analyte biomarkers are not sufficient at identifying who will benefit from the drugs. More advanced predictive diagnostics like OncoPrism are more robust and better at helping physicians determine a patient’s a treatment path that includes immunotherapy and avoids the toxicities of treatments like chemotherapy.
"Improving our ability to predict which patients will respond to which immunotherapies is key to helping us match the right treatment to the right patient at the right time," said A. Dimitrios Colevas, MD, Professor of Oncology and of Radiation Oncology at Stanford Cancer Center, "We have excellent immunotherapies available, but today’s diagnostic tools are limited in identifying all of the patients that can benefit. We are excited to join the PREDAPT study and explore how new predictive diagnostics may be able to help us connect more patients with powerful drugs that can help them."
"The addition of Stanford University to the impressive list of clinical partners participating in the PREDAPT trial validates the potential of our predictive diagnostic approach to accelerate therapeutic matchmaking, getting patients the right drugs more quickly and thereby improving, and even extending, their lives," said Cofactor Genomics CEO Jarret Glasscock.